These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15884041)

  • 21. Comparing LRRK2 Gly2385Arg carriers with noncarriers.
    Tan EK; Fook-Chong S; Yi Z
    Mov Disord; 2007 Apr; 22(5):749-50. PubMed ID: 17290460
    [No Abstract]   [Full Text] [Related]  

  • 22. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Jankovic J
    Ann Neurol; 2005 Jun; 57(6):933-4. PubMed ID: 15929036
    [No Abstract]   [Full Text] [Related]  

  • 23. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases.
    Hernandez D; Paisan Ruiz C; Crawley A; Malkani R; Werner J; Gwinn-Hardy K; Dickson D; Wavrant Devrieze F; Hardy J; Singleton A
    Neurosci Lett; 2005 Dec; 389(3):137-9. PubMed ID: 16102903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics.
    Bonifati V
    Eur J Hum Genet; 2006 Oct; 14(10):1061-2. PubMed ID: 16835587
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mutation in LRRK2 is associated with familial presentation of Parkinson's disease in a Chilean kindred].
    Miranda M
    Rev Med Chil; 2007 Mar; 135(3):406-7. PubMed ID: 17505590
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical heterogeneity of the LRRK2 G2019S mutation.
    Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
    Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred.
    Gosal D; Lynch T; Ross OA; Haugarvoll K; Farrer MJ; Gibson JM
    Mov Disord; 2007 Jan; 22(2):291-2. PubMed ID: 17089395
    [No Abstract]   [Full Text] [Related]  

  • 28. Genetics of Parkinson's disease: LRRK2 on the rise.
    Brice A
    Brain; 2005 Dec; 128(Pt 12):2760-2. PubMed ID: 16311269
    [No Abstract]   [Full Text] [Related]  

  • 29. How much does dardarin contribute to Parkinson's disease?
    Brice A
    Lancet; 2005 Jan 29-Feb 4; 365(9457):363-4. PubMed ID: 15680438
    [No Abstract]   [Full Text] [Related]  

  • 30. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease.
    Funalot B; Nichols WC; Pérez-Tur J; Mercier G; Lucotte G
    Genet Test; 2006; 10(4):290-3. PubMed ID: 17253937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From GWAS to clinical utility in Parkinson's disease.
    Klein C; Ziegler A
    Lancet; 2011 Feb; 377(9766):613-4. PubMed ID: 21292316
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: The G2019S LRRK2 mutation is uncommon amongst Greek patients with familial Parkinson's disease.
    Papapetropoulos S; Argyriou AA; Mitsi G; Chroni E
    Eur J Neurol; 2007 Nov; 14(11):e6. PubMed ID: 17956439
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
    Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
    Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 G2019S mutations may be increased in Puerto Ricans.
    Saunders-Pullman R; Cabassa J; San Luciano M; Stanley K; Raymond D; Ozelius LJ; Bressman SB
    Mov Disord; 2011 Aug; 26(9):1772-3. PubMed ID: 21449009
    [No Abstract]   [Full Text] [Related]  

  • 35. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease.
    Haubenberger D; Bonelli S; Hotzy C; Leitner P; Lichtner P; Samal D; Katzenschlager R; Djamshidian A; Brücke T; Steffelbauer M; Bancher C; Grossmann J; Ransmayr G; Strom TM; Meitinger T; Gasser T; Auff E; Zimprich A
    Mov Disord; 2007 Aug; 22(11):1640-3. PubMed ID: 17523199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.
    Ozelius LJ; Senthil G; Saunders-Pullman R; Ohmann E; Deligtisch A; Tagliati M; Hunt AL; Klein C; Henick B; Hailpern SM; Lipton RB; Soto-Valencia J; Risch N; Bressman SB
    N Engl J Med; 2006 Jan; 354(4):424-5. PubMed ID: 16436782
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.
    Zabetian CP; Lauricella CJ; Tsuang DW; Leverenz JB; Schellenberg GD; Payami H
    Arch Neurol; 2006 Jan; 63(1):156-7. PubMed ID: 16401756
    [No Abstract]   [Full Text] [Related]  

  • 38. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.
    Lesage S; Dürr A; Tazir M; Lohmann E; Leutenegger AL; Janin S; Pollak P; Brice A;
    N Engl J Med; 2006 Jan; 354(4):422-3. PubMed ID: 16436781
    [No Abstract]   [Full Text] [Related]  

  • 39. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease.
    Bialecka M; Hui S; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Neurosci Lett; 2005 Dec; 390(1):1-3. PubMed ID: 16115731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease.
    Lu CS; Simons EJ; Wu-Chou YH; Fonzo AD; Chang HC; Chen RS; Weng YH; Rohé CF; Breedveld GJ; Hattori N; Gasser T; Oostra BA; Bonifati V
    Parkinsonism Relat Disord; 2005 Dec; 11(8):521-2. PubMed ID: 16256409
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.